BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...He succeeds Pascale Boissel, who is stepping down for personal reasons. Lieber was CFO at Histogenics Corp....
BioCentury | Jun 5, 2019
Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

...Cambridge, Mass.) hired Stephen Kennedy as SVP, head of technical operations. He was COO at Histogenics Corp....
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

...Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and...
...90% of the resulting company, which will trade on NASDAQ and be named Ocugen Inc. Histogenics Corp....
...candidate (see "Histogenics' NeoCart Misses in Phase III for Knee Cartilage Repair" ). Shannon Lehnbeuter, Staff Writer Histogenics Corp. Ocugen...
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
BioCentury | Sep 21, 2018
Clinical News

Histogenics' NeoCart misses in Phase III for knee cartilage repair

...subscore assessment and a ≥20-point improvement in the International Knee Documentation Committee (IKDC) subjective assessment. Histogenics...
...that the candidate did significantly improve pain and function at six months vs. microfracture (p=0.018). Histogenics Corp....
...IKDC) score; cartilage repair as measured by MRI Status: Phase III data Milestone: NA Jaime De Leon NeoCart Histogenics Corp....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Dravet syndrome Ph III data 2H18 Heron Therapeutics Inc. (NASDAQ:HRTX) HTX-011 Pain Submit NDA 2H18 Histogenics Corp....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...4Q18 Heron Therapeutics Inc. (NASDAQ:HRTX) HTX-011 Postoperative pain Ph III data; submit NDA 1H18; 2018 Histogenics Corp....
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...CEO Stanley Erck will be interim CFO while the company seeks a replacement. Musculoskeletal company Histogenics Corp....
Items per page:
1 - 10 of 63
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...He succeeds Pascale Boissel, who is stepping down for personal reasons. Lieber was CFO at Histogenics Corp....
BioCentury | Jun 5, 2019
Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

...Cambridge, Mass.) hired Stephen Kennedy as SVP, head of technical operations. He was COO at Histogenics Corp....
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

...Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and...
...90% of the resulting company, which will trade on NASDAQ and be named Ocugen Inc. Histogenics Corp....
...candidate (see "Histogenics' NeoCart Misses in Phase III for Knee Cartilage Repair" ). Shannon Lehnbeuter, Staff Writer Histogenics Corp. Ocugen...
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
BioCentury | Sep 21, 2018
Clinical News

Histogenics' NeoCart misses in Phase III for knee cartilage repair

...subscore assessment and a ≥20-point improvement in the International Knee Documentation Committee (IKDC) subjective assessment. Histogenics...
...that the candidate did significantly improve pain and function at six months vs. microfracture (p=0.018). Histogenics Corp....
...IKDC) score; cartilage repair as measured by MRI Status: Phase III data Milestone: NA Jaime De Leon NeoCart Histogenics Corp....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Dravet syndrome Ph III data 2H18 Heron Therapeutics Inc. (NASDAQ:HRTX) HTX-011 Pain Submit NDA 2H18 Histogenics Corp....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...4Q18 Heron Therapeutics Inc. (NASDAQ:HRTX) HTX-011 Postoperative pain Ph III data; submit NDA 1H18; 2018 Histogenics Corp....
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...CEO Stanley Erck will be interim CFO while the company seeks a replacement. Musculoskeletal company Histogenics Corp....
Items per page:
1 - 10 of 63